Stockscreener 앱 받기
84.53
0.46%
0.375
전일 마감가:
$84.15
열려 있는:
$83.54
하루 거래량:
4.34M
Relative Volume:
0.88
시가총액:
$48.68B
수익:
$6.30B
순이익/손실:
$1.07B
주가수익비율:
45.92
EPS:
1.8406
순현금흐름:
$1.34B
1주 성능:
+3.80%
1개월 성능:
+6.55%
6개월 성능:
+4.60%
1년 성능:
+11.18%
1일 변동 폭
$83.22
$84.79
1주일 범위
$79.19
$84.79
52주 변동 폭
$72.30
$87.89
에드워즈라이프사이언시스 Stock (EW) Company Profile
명칭
Edwards Lifesciences Corp
전화
(949) 250-2500
주소
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, SYK, MDT, BSX
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
84.43 | 48.52B | 6.30B | 1.07B | 1.34B | 1.8406 |
ABT
Abbott Laboratories
|
92.68 | 158.35B | 45.13B | 6.28B | 7.40B | 3.5895 |
SYK
Stryker Corp
|
329.11 | 125.43B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
83.00 | 106.97B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
60.34 | 92.25B | 20.62B | 3.56B | 3.66B | 2.3847 |
에드워즈라이프사이언시스 Stock (EW) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-01 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2026-01-09 | 업그레이드 | TD Cowen | Hold → Buy |
| 2025-12-18 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2025-11-03 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2025-10-29 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-10-29 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-10-07 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-07-29 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2025-04-24 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | 업그레이드 | Stifel | Hold → Buy |
| 2025-01-16 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-10-11 | 재개 | Morgan Stanley | Equal-Weight |
| 2024-09-18 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-07-31 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-07-25 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-25 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2024-07-25 | 다운그레이드 | Truist | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-05-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-05-14 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-03-07 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-02-02 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-11-28 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-07-19 | 개시 | Robert W. Baird | Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Overweight |
| 2023-03-29 | 개시 | UBS | Neutral |
| 2023-03-08 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | 다운그레이드 | Bernstein | Outperform → Underperform |
| 2023-01-30 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-10-28 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-10-26 | 개시 | Mizuho | Buy |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-07-29 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | 개시 | Truist | Buy |
| 2022-04-06 | 개시 | Wolfe Research | Outperform |
| 2022-03-16 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | 재개 | BofA Securities | Neutral |
| 2022-02-02 | 업그레이드 | UBS | Neutral → Buy |
| 2022-01-27 | 재확인 | Citigroup | Buy |
| 2022-01-27 | 재확인 | Evercore ISI | Outperform |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | Stifel | Buy |
| 2022-01-27 | 재확인 | UBS | Neutral |
| 2021-12-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-12-15 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-12-06 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | 재확인 | Canaccord Genuity | Buy |
| 2021-07-30 | 재확인 | Deutsche Bank | Hold |
| 2021-07-30 | 재확인 | Jefferies | Buy |
| 2021-07-30 | 재확인 | Morgan Stanley | Overweight |
| 2021-07-30 | 재확인 | Oppenheimer | Outperform |
| 2021-07-30 | 재확인 | Stifel | Buy |
| 2021-07-30 | 재확인 | UBS | Neutral |
| 2021-07-30 | 재확인 | Wells Fargo | Equal Weight |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-04-05 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-12-11 | 재확인 | Canaccord Genuity | Buy |
| 2020-09-11 | 개시 | Wolfe Research | Underperform |
| 2020-04-28 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-10 | 개시 | Oppenheimer | Outperform |
| 2020-01-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-10-24 | 재확인 | Canaccord Genuity | Buy |
| 2019-09-23 | 개시 | Piper Jaffray | Overweight |
| 2019-07-24 | 재확인 | BofA/Merrill | Buy |
| 2019-03-18 | 재확인 | Canaccord Genuity | Buy |
| 2019-01-18 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | 개시 | Deutsche Bank | Hold |
| 2018-11-28 | 개시 | UBS | Neutral |
| 2018-10-16 | 개시 | Barclays | Underweight |
| 2018-10-02 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
모두보기
에드워즈라이프사이언시스 주식(EW)의 최신 뉴스
Vanguard Group Inc. Sells 283,775 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
US28176EAD04 Bond Analysis — Key Metrics - TradingView
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MSN
Munich Reinsurance Co Stock Corp in Munich Purchases 52,494 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
A Look at Edwards Lifesciences Corp (EW) After 5.6% Gain -- GF V - GuruFocus
Edwards Lifesciences Stock Surges On Heart Valve Devices Growth - Benzinga
Edwards raises 2026 guidance on strong TAVR performance - BioWorld News
Edwards Lifesciences jumps 5.2% as Q1 results top expectations and full-year guidance rises - Quiver Quantitative
TD Cowen reiterates Edwards Lifesciences stock Buy rating on strong Q1 results - Investing.com
Edwards Lifesciences raises FY26 guidance following strong Q1 - Medical Device Network
Bernstein SocGen raises Edwards Lifesciences stock price target to $96 - Investing.com
Stifel reiterates Edwards Lifesciences stock rating on strong Q1 beat - Investing.com
Stifel reiterates Edwards Lifesciences stock rating on strong Q1 beat By Investing.com - Investing.com Canada
Edwards Lifesciences (NYSE:EW) Given New $87.00 Price Target at Robert W. Baird - MarketBeat
Edwards Lifesciences (NYSE:EW) Price Target Raised to $100.00 at BTIG Research - MarketBeat
OLD National Bancorp IN Sells 16,066 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Bernstein Adjusts PT on Edwards Lifesciences to $96 From $95, Maintains Market Perform Rating - marketscreener.com
Teacher Retirement System of Texas Has $23.75 Million Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Canaccord Genuity Adjusts PT on Edwards Lifesciences to $85 From $87, Maintains Hold Rating - marketscreener.com
Goldman Sachs Adjusts Price Target on Edwards Lifesciences to $98 From $97, Maintains Buy Rating - marketscreener.com
BTIG raises Edwards Lifesciences stock price target on strong Q1 beat - Investing.com Australia
BTIG raises Edwards Lifesciences stock price target on strong Q1 beat By Investing.com - Investing.com South Africa
Truist raises Edwards Lifesciences stock price target on TAVR growth - Investing.com
Barclays raises Edwards Lifesciences stock price target on EBITDA outlook - Investing.com
Truist raises Edwards Lifesciences stock price target on TAVR growth By Investing.com - Investing.com Canada
EW Technical Analysis | Trend, Signals & Chart Patterns | EDWARDS LIFESCIENCES CORP (NYSE:EW) - ChartMill
Edwards Lifesciences Corp (EW) Q1 2026 Earnings Call Highlights: - GuruFocus
Edwards Lifesciences Q1 Earnings Call Highlights - MarketBeat
Edwards Lifesciences reports Q1 EPS 78c, consensus 73c - TipRanks
Earnings call transcript: Edwards Lifesciences Q1 2026 beats expectations By Investing.com - Investing.com South Africa
Edwards Lifesciences (EW) Raises FY26 Sales Growth Guidance - GuruFocus
Earnings call transcript: Edwards Lifesciences Q1 2026 beats expectations - Investing.com
Transcript: Edwards Lifesciences Q1 2026 Earnings Conference Call - Benzinga
Is Edwards Lifesciences (EW) Still 13.6% Undervalued After Q1 20 - GuruFocus
Edwards Lifesciences Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Q1 2026 Edwards Lifesciences Corp Earnings Call Transcript - GuruFocus
Edwards Lifesciences (NYSE:EW) Releases Q2 2026 Earnings Guidance - MarketBeat
Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Edwards Lifesciences options imply 5.2% move in share price post-earnings - TipRanks
Edwards Lifesciences (EW) Stock Rises on Q1 2026 Earnings - Quiver Quantitative
Edwards Lifesciences shares rise 4% as guidance raised following Q1 earnings beat - Investing.com Canada
Edwards Lifesciences shares rise 4% as guidance raised following Q1 earnings beat By Investing.com - Investing.com India
Edwards Lifesciences Q1 Earnings, Revenue Rise - marketscreener.com
Edwards Lifesciences (NYSE:EW) Releases Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat
Edwards Lifesciences reports Q1 revenue $1.65B, raises 2026 sales and adjusted EPS guidance - TradingView
Stronger Q1 boosts 2026 outlook for Edwards Lifesciences (NYSE: EW) - Stock Titan
Heart-valve demand drives Edwards to raise 2026 forecast - Stock Titan
Edwards Lifesciences earnings on deck as TAVR share gains loom By Investing.com - Investing.com South Africa
Edwards Lifesciences earnings on deck as TAVR share gains loom - Investing.com
Edwards Lifesciences Q1 2026 Earnings Call Transcript - MarketBeat
Edwards Lifesciences Corp. Experiences Valuation Adjustment Amid Competitive Market Landscape - Markets Mojo
에드워즈라이프사이언시스 (EW) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.90%
자본화:
|
볼륨(24시간):